Recombinant Anti-Myelin Protein Zero antibody [EPR20383] (ab183868)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR20383] to Myelin Protein Zero
- Suitable for: IP, WB, IHC-P, IHC-Fr
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Myelin Protein Zero antibody [EPR20383]
See all Myelin Protein Zero primary antibodies -
Description
Rabbit monoclonal [EPR20383] to Myelin Protein Zero -
Host species
Rabbit -
Tested applications
Suitable for: IP, WB, IHC-P, IHC-Frmore details
Unsuitable for: ICC -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Recombinant full length protein. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human, mouse and rat sciatic nerve lysates. IHC-P: Human peripheral nerves; Mouse and rat sciatic nerves. IHC-Fr: Mouse and rat sciatic nerves.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR20383 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab183868 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
1/20.
|
|
WB |
1/1000. Detects a band of approximately 26-28 kDa (predicted molecular weight: 28 kDa).
|
|
IHC-P | (1) |
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
IHC-Fr |
1/50.
|
Notes |
---|
IP
1/20. |
WB
1/1000. Detects a band of approximately 26-28 kDa (predicted molecular weight: 28 kDa). |
IHC-P
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
IHC-Fr
1/50. |
Target
-
Function
Creation of an extracellular membrane face which guides the wrapping process and ultimately compacts adjacent lamellae. -
Tissue specificity
Found only in peripheral nervous system Schwann cells. -
Involvement in disease
Defects in MPZ are the cause of Charcot-Marie-Tooth disease type 1B (CMT1B) [MIM:118200]. CMT1B is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT1 group are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.
Defects in MPZ are the cause of Charcot-Marie-Tooth disease type 2I (CMT2I) [MIM:607677]. CMT2I is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2I is characterized by late onset (range 47 to 60 years).
Defects in MPZ are the cause of Charcot-Marie-Tooth disease type 2J (CMT2J) [MIM:607736]. CMT2J is a form of Charcot-Marie-Tooth disease characterized by the association of axonal peripheral neuropathy with hearing loss and pupillary abnormalities such as Adie pupil. Inheritance is autosomal dominant.
Defects in MPZ are the cause of Adie pupil (ADIEP) [MIM:103100]. A stationary, benign disorder characterized by tonic, sluggishly reacting pupil and hypoactive or absent tendon reflexes. Adie pupil is a characteristic of Charcot-Marie-Tooth disease type 2J.
Defects in MPZ may be the cause of Charcot-Marie-Tooth disease dominant intermediate type D (CMTDID) [MIM:607791]. CMTDID is a form of Charcot-Marie-Tooth disease characterized by features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.
Defects in MPZ are a cause of Dejerine-Sottas syndrome (DSS) [MIM:145900]; also known as Dejerine-Sottas neuropathy (DSN) or hereditary motor and sensory neuropathy III (HMSN3). DSS is a severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. DSS is characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome.
Defects in MPZ are a cause of congenital hypomyelination neuropathy (CHN) [MIM:605253]. CHN is characterized clinically by early onset of hypotonia, areflexia, distal muscle weakness, and very slow nerve conduction velocities.
Defects in MPZ are a cause of Roussy-Levy syndrome (ROULS) [MIM:180800]; also known as Roussy-Levy hereditary areflexic dystasia. This autosomal dominant disorder resembles Charcot-Marie-Tooth disease type 1 in that it presents with foot deformity, weakness and atrophy of distal limb muscles, especially the peronei, and absent tendon reflexes. The phenotype differs, however, in that it includes static tremor of the upper limbs and gait ataxia. -
Sequence similarities
Belongs to the myelin P0 protein family.
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Post-translational
modificationsN-glycosylated; contains sulfate-substituted glycan. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 4359 Human
- Entrez Gene: 17528 Mouse
- Entrez Gene: 24564 Rat
- Omim: 159440 Human
- SwissProt: P25189 Human
- SwissProt: P27573 Mouse
- SwissProt: P06907 Rat
- Unigene: 591486 Human
see all -
Alternative names
- Charcot Marie Tooth neuropathy 1B antibody
- CHM antibody
- CMT1 antibody
see all
Images
-
All lanes : Anti-Myelin Protein Zero antibody [EPR20383] (ab183868) at 1/5000 dilution
Lane 1 : Mouse sciatic nerve lysate
Lane 2 : Mouse liver lysate
Lane 3 : Mouse brain lysate
Lane 4 : Rat sciatic nerve lysate
Lane 5 : Rat liver lysate
Lane 6 : Rat brain lysate
Lysates/proteins at 4 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 28 kDa
Observed band size: 26-28 kDa why is the actual band size different from the predicted?
Exposure time: 1 secondBlocking/Dilution buffer: 5% NFDM/TBST.
The MW observed is consistent with the literature (PMID 10704451; PMID 1384988).
Negative control: liver, brain tissue (PMID 2578885, PMID 25288117).
-
Immunohistochemical analysis of paraffin-embedded human peripheral nerves labeling Myelin Protein Zero with ab183868 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use.
Membranous staining on Schwann cells of human peripheral nerves (PMID: 21057508).
Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemical analysis of 4% paraformaldehyde-fixed, 0.2% Triton X-100 permeabilized frozen mouse sciatic nerves labeling Myelin Protein Zero with ab183868 at 1/50 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).
Membranous staining on Schwann cells of mouse sciatic nerves (PMID: 21057508).
The nuclear counterstain is DAPI (blue).
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) at 1/1000 dilution.
-
Myelin Protein Zero was immunoprecipitated from Human Sciatic Nerve lysate with ab183868 at 1/20 dilution. Western blot was performed from the immunoprecipitate using ab183868 at 1/5000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10,000 dilution.
Lane 1: Human Sciatic Nerve lysate 10ug (Input).
Lane 2: ab183868 IP in Human Sciatic Nerve lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab183868 in Human Sciatic Nerve lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
-
Immunohistochemical analysis of paraffin-embedded mouse sciatic nerves labeling Myelin Protein Zero with ab183868 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use.
Membranous staining on Schwann cells of mouse sciatic nerves (PMID: 21057508).
Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
All lanes : Anti-Myelin Protein Zero antibody [EPR20383] (ab183868) at 1/1000 dilution
Lane 1 : Human sciatic nerve lysate
Lane 2 : Human fetal liver lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 28 kDa
Observed band size: 26-28 kDa why is the actual band size different from the predicted?
Exposure time: 30 secondsBlocking/Dilution buffer: 5% NFDM/TBST.
The MW observed is consistent with the literature (PMID 10704451; PMID 1384988).
Negative control: liver tissue (PMID 2578885).
-
Immunohistochemical analysis of 4% paraformaldehyde-fixed, 0.2% Triton X-100 permeabilized frozen rat sciatic nerves labeling Myelin Protein Zero with ab183868 at 1/50 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).
Membranous staining on Schwann cells of rat sciatic nerves (PMID: 21057508).
The nuclear counterstain is DAPI (blue).
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) at 1/1000 dilution.
-
Immunohistochemical analysis of paraffin-embedded rat sciatic nerves labeling Myelin Protein Zero with ab183868 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use.
Membranous staining on Schwann cells of rat sciatic nerves (PMID: 21057508).
Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (5)
ab183868 has been referenced in 5 publications.
- Sadri M et al. Tumor necrosis factor receptor-1 is selectively sequestered into Schwann cell extracellular vesicles where it functions as a TNFα decoy. Glia 70:256-272 (2022). PubMed: 34559433
- Di Z et al. Single-cell and WGCNA uncover a prognostic model and potential oncogenes in colorectal cancer. Biol Proced Online 24:13 (2022). PubMed: 36117173
- Bonnet M et al. Immediate or Delayed Transplantation of a Vein Conduit Filled with Nasal Olfactory Stem Cells Improves Locomotion and Axogenesis in Rats after a Peroneal Nerve Loss of Substance. Int J Mol Sci 21:N/A (2020). PubMed: 32290426
- Elsayed H et al. Development and Characterisation of an in vitro Model of Wallerian Degeneration. Front Bioeng Biotechnol 8:784 (2020). PubMed: 32754584
- Brifault C et al. Deletion of the Gene Encoding the NMDA Receptor GluN1 Subunit in Schwann Cells Causes Ultrastructural Changes in Remak Bundles and Hypersensitivity in Pain Processing. J Neurosci 40:9121-9136 (2020). PubMed: 33051351